Welcome to the Irish Medical Times website
This site is aimed at healthcare professionals.
Are you a healthcare professional?
NB: We use cookies to help personalise your web experience and comply with Irish healthcare law. Whatever your choice, you are agreeing to our use of cookies. Please close this browser tab if you don't want to proceed.
This site contains information, news and advice for healthcare professionals.
You have informed us that you are not a healthcare professional and therefore we are unable to provide you with access to this site.

May 2, 2016

Diabetes and Insulin Preparations

Download PDF Click on image to enlarge The above table was prepared from data available in March 2016 and lists products that are currently included in MIMS Ireland. Prescribers should refer to section 6.4 of MIMS Ireland and SPCs of each product for full up-to-date details of licensing. MIMS Ireland Copyright®

High-Strength Insulin Preparations

Several new high-strength insulin products have been approved for use throughout the EU since 2013*. High-strength insulin products contain a concentration of insulin which exceeds the standard 100 units/ml (e.g. they may contain 200 units/ml or 300 units/ml) and provides for a better dissolution profile over the duration of action, helping to meet an increasing […]

Lenvima ▼

Company: Eisai Ltd. Legal category: Prescription. High tech reimbursable. Sport permitted. Active ingredient: Lenvatinib (as mesilate) 4mg, 10mg. Description: Hard capsule with yellowish-red or yellow body and yellowish-red cap, marked with e on cap, and LENV 4 mg or LENV 10 mg on body, respectively. Presentation: 4mg-30, €1989.80; 10mg-30, €1989.80. Indications: Treatment of adults with […]


Company: Astellas Pharma Co Ltd. Legal category: Prescription. GMS reimbursable. Sport permitted. Active ingredients: Solifenacin succinate/ tamsulosin hydrochloride 6/0.4mg. Description: Round red film-coated modified release tablet marked 6/0.4. Presentation: 30. Indications: Treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are […]

Praxbind ▼ Approved for the Specific Reversal of the Anticoagulant Effects of Pradaxa

Download PDF   Boehringer Ingelheim Ltd. is pleased to announce that Praxbind (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa (dabigatran etexilate) in cases of emergency surgery/urgent procedures or in situations of life-threatening or uncontrolled bleeding, is now available in Ireland. Idarucizumab is the first specific reversal agent for a […]

Anticoagulant Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation

Download PDF   Stroke in Ireland – Facts and Figures Each year, approximately 10,000 people are admitted to hospitals in Ireland with acute stroke and around 2,000 die – more deaths than breast cancer, prostate cancer and bowel cancer combined. An estimated 30,000 people are living in the community with disabilities as a result of […]

Brief Overview of the Outcomes from Pivotal Clinical Trials Comparing the Efficacy and Safety of NOACs with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation

Download PDF   Dabigatran1 Efficacy and safety was investigated in the RE-LY trial, a randomised, non-inferiority trial, designed to compare two fixed doses of dabigatran (150mg and 110mg), each administered in a blinded manner, with open-label use of warfarin [target INR, 2.0 to 3.0] in patients with AF and at increased risk for stroke (n=18,113 […]

Overview of Pharmacological Properties of Warfarin and Novel Oral Anticoagulants (NOACs)

Download PDF Click on image to enlarge

Reminder – Oral methotrexate and risk of unintentional overdose due to medication errors

The Health Products Regulatory Authority (HPRA) would like to remind healthcare professionals of the need for vigilance when prescribing, dispensing and/or counselling patients in relation to methotrexate. Oral methotrexate* is indicated in the treatment of active rheumatoid arthritis, adult psoriasis and in a number of oncological indications, with differing dosage regimens for the respective indications […]

Ibuprofen: Review confirms small increased cardiovascular risk with daily doses at or above 2,400mg

Non-steroidal anti-inflammatory drugs (NSAIDs) are valuable therapeutic agents in the treatment of pain and inflammation and the risk-benefit profile of these medicines has been closely monitored nationally and at EU level. Previous EU reviews have confirmed that NSAIDs, as a class, are associated with a small increased risk of arterial thromboembolic events (such as myocardial […]

Next Page »